Clinical Implications of Immune Checkpoints and the RANK/RANK-L Signaling Pathway in High-Grade Canine Mast Cell Tumors

Simple Summary This study aimed to characterize the molecular profiles of immune checkpoints RANK/RANK-L and IFN-γ in high-grade mast cell tumors and lymph node metastases to understand the complex activities occurring in the tumor microenvironment. All tumors showed moderate or intense immunolabeling of PD-L1, CTLA-4, RANK, RANK-L, and IFN-γ, and the lymph node metastases presented moderate or intense immunolabeling of checkpoint proteins. In conclusion, the high-grade MCTs were characterized as immunosuppressive microenvironments, showing an increase in the RANK/RANK-L signaling pathway and intensified immune checkpoint immunoreactivity, which may explain an intratumoral escape mechanism and indicating high sensitivity to immunotherapy. Therefore, PD-L1, RANK/RANK-L and IFN-γ may be useful in the clinical management of dogs with high-grade MCT. Abstract Mast cell tumors (MCTs) are the most common malignant cutaneous tumors in dogs, and they present extremely variable biological behavior. The interaction between RANK, RANK-L, and immune checkpoints is frequently detected in the tumor microenvironment, and, together, they participate in every stage of cancer development. Thus, the aim of this study was to characterize the molecular profiles of PD-L1, CTLA-4, RANK/RANK-L signaling pathway, and IFN-γ in primary tumors and lymph node metastases. Formalin-fixed, paraffin-embedded slides of MCTs and metastatic lymph nodes of ten dogs were submitted to immunohistochemical investigations. The results demonstrated that the tumor microenvironment of the high-grade mast cell tumors showed moderate or intense immunolabeling of all proteins, and the lymph node metastases also showed moderate or intense immunolabeling of checkpoint proteins. In addition, MCTs larger than 3 cm were associated with intensified PD-L1 (p = 0.03) in metastatic lymph nodes and RANK-L (p = 0.049) immunoreactivity in the tumor. Furthermore, dogs with a survival time of less than 6 months showed higher PD-L1 immunoreactivity (p = 0.042). In conclusion, high-grade MCT is associated with an immunosuppressive microenvironment that exhibits elevated RANK/RANK-L signaling and enhanced immune checkpoint immunoreactivity, potentially facilitating intratumorally immune escape. These biomarkers show promise as clinical indicators of disease progression and might response to immunotherapy in dogs with high-grade MCTs, thus emphasizing their importance for guiding treatment decisions and improving outcomes.

[1]  Bianca Ribeiro de Souza,et al.  OncoTherad^® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer , 2022, Journal of Cancer Research and Clinical Oncology.

[2]  D. Driemeier,et al.  Pathological aspects of cutaneous mast cell tumors with metastases in 49 dogs , 2022, Veterinary pathology.

[3]  L. Marconato,et al.  Lymphadenectomy improves outcome in dogs with resected Kiupel high-grade cutaneous mast cell tumours and overtly metastatic regional lymph nodes. , 2022, The Journal of small animal practice.

[4]  Nicolas Liaudet,et al.  IFN-γ–dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis , 2022, Science advances.

[5]  R. Laufer-Amorim,et al.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors , 2022, Cells.

[6]  E. Socca,et al.  OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway. , 2022, Tissue & cell.

[7]  J. Machiels,et al.  Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors , 2021, Clinical Cancer Research.

[8]  B. Strauss,et al.  Current Status of Canine Melanoma Diagnosis and Therapy: Report From a Colloquium on Canine Melanoma Organized by ABROVET (Brazilian Association of Veterinary Oncology) , 2021, Frontiers in Veterinary Science.

[9]  S. Casimiro,et al.  The Roadmap of RANKL/RANK Pathway in Cancer , 2021, Cells.

[10]  Shuiping Gao,et al.  Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors , 2021, Therapeutic advances in medical oncology.

[11]  R. Rasotto,et al.  Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group , 2021, Veterinary pathology.

[12]  F. Queiroga,et al.  Prognostic value of immunohistochemical markers in canine cutaneous mast cell tumours: A systematic review and meta-analysis. , 2021, Veterinary and comparative oncology.

[13]  A. Davtyan,et al.  CTLA-4 in Regulatory T Cells for Cancer Immunotherapy , 2021, Cancers.

[14]  M. Walsh,et al.  Regulation of T cell-associated tissues and T cell activation by RANKL-RANK-OPG , 2021, Journal of Bone and Mineral Metabolism.

[15]  J. Munday,et al.  Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. , 2020, Veterinary immunology and immunopathology.

[16]  M. Merad,et al.  PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer , 2020, Nature Cancer.

[17]  C. Klein,et al.  Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy , 2020, Science Translational Medicine.

[18]  Xiaoqiu Wu,et al.  RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies , 2020, Frontiers in Cell and Developmental Biology.

[19]  N. Durán,et al.  New Therapeutic Perspective for Bladder Cancer in Dogs: Toxicological and Clinical Effects of OncoTherad Nanostructured Immunotherapy , 2019, Journal of Physics: Conference Series.

[20]  G. Bergers,et al.  Tumors vs. Chronic Wounds: An Immune Cell's Perspective , 2019, Front. Immunol..

[21]  F. Redegeld,et al.  Role of Mast Cells in Shaping the Tumor Microenvironment , 2019, Clinical Reviews in Allergy & Immunology.

[22]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of experimental & clinical cancer research : CR.

[23]  N. Durán,et al.  Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK/RANKL signaling: New therapeutic perspective for non-muscle invasive bladder cancer. , 2019, Journal of Clinical Oncology.

[24]  S. Sudarsanam,et al.  Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases , 2019, Modern Pathology.

[25]  J. Paty,et al.  Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. , 2019, The Lancet. Oncology.

[26]  M. Kneilling,et al.  Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. , 2018, JCI insight.

[27]  A. Broeks,et al.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[28]  A. Copik,et al.  PD-L1 blockade enhances anti-tumor efficacy of NK cells , 2018, Oncoimmunology.

[29]  H. Inokuma,et al.  Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma , 2018, PloS one.

[30]  L. Ni,et al.  Interferon gamma in cancer immunotherapy , 2018, Cancer medicine.

[31]  G. Kristiansen,et al.  CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. , 2018, JCI insight.

[32]  A. Gupta,et al.  Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab , 2018, Clinical Cancer Research.

[33]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[34]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[35]  L. Marconato,et al.  Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: A prospective study , 2018, Veterinary and comparative oncology.

[36]  W. Dougall,et al.  RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer , 2018, Oncoimmunology.

[37]  R. Rosell,et al.  Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients , 2018, Therapeutic advances in medical oncology.

[38]  Yoshiyuki Suzuki,et al.  PD‐L1 expression is mainly regulated by interferon gamma associated with JAK‐STAT pathway in gastric cancer , 2017, Cancer science.

[39]  Johannes Griss,et al.  Tumor-associated B-cells induce tumor heterogeneity and therapy resistance , 2017, Nature Communications.

[40]  Yinying Wu,et al.  PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma , 2017, Oncology letters.

[41]  D. He,et al.  Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→AKT→GSK3β→AM signaling , 2017, Oncogene.

[42]  M. Heymann,et al.  RANK–RANKL signalling in cancer , 2016, Bioscience reports.

[43]  L. Galluzzi,et al.  Prevention of breast cancer by RANKL/RANK blockade , 2016, Cell Research.

[44]  K. Ohashi,et al.  Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma , 2016, PloS one.

[45]  Kumi Y. Inoue,et al.  Programmed Cell Death Ligand 1 Expression in Canine Cancer. , 2016, In vivo.

[46]  G. Marone,et al.  Tumor-Associated Mast Cells in Thyroid Cancer , 2015, International journal of endocrinology.

[47]  J. Pollard,et al.  Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.

[48]  K. Ohashi,et al.  Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade , 2014, PloS one.

[49]  D. Chang,et al.  Lymphatic Territories (Lymphosomes) in a Canine: An Animal Model for Investigation of Postoperative Lymphatic Alterations , 2013, PloS one.

[50]  M. Pistillo,et al.  Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer , 2012, Cancer Immunology, Immunotherapy.

[51]  A. Trautmann,et al.  Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. , 2011, The Journal of investigative dermatology.

[52]  J D Webster,et al.  Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior , 2011, Veterinary pathology.

[53]  A. Sharma,et al.  Mast cells: emerging sentinel innate immune cells with diverse role in immunity. , 2010, Molecular immunology.

[54]  Haidong Dong,et al.  PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.

[55]  A. Potti,et al.  Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation , 2006, Cancer.

[56]  N. Xu,et al.  Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. , 2006, Acta histochemica.

[57]  A. Qattan,et al.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.

[58]  J. Resau,et al.  The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. , 2006, Neoplasia.

[59]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[60]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[61]  J. Okamura,et al.  Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis , 1999, Gastric Cancer.

[62]  S. Galli,et al.  Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. , 1999, Experimental hematology.

[63]  E. Macewen,et al.  Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs , 1984, Veterinary pathology.

[64]  J. Lawrence,et al.  Withrow & MacEwen's Small Animal Clinical Oncology , 2013 .

[65]  T. Fan,et al.  Expression of receptor activator of nuclear factor κ-B ligand (RANKL) in neoplasms of dogs and cats , 2007 .